22744-42-9

Basic information

• Product Name: Benzamide, 4-hydroxy-N-(4-hydroxyphenyl)-
• Synonyms: 4-hydroxy-N-(4-hydroxyphenyl)benzamide
• CAS NO: 22744-42-9
• Molecular Formula: C₁₃H₁₁NO₃
• Molecular Weight: 229.23
• Mol File: 22744-42-9.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzamide, 4-hydroxy-N-(4-hydroxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 4-hydroxy-N-(4-hydroxyphenyl)-(22744-42-9)
• EPA Substance Registry System: Benzamide, 4-hydroxy-N-(4-hydroxyphenyl)-(22744-42-9)

Safety Data

• Hazardous Substances Data: 22744-42-9(Hazardous Substances Data)

Upstream product

• 611-99-4 4,4'-Dihydroxybenzophenone 
• 28141-24-4 4-hydroxybenzoyl chloride 
• 123-30-8 4-amino-phenol 
• 27914-73-4 4-acetoxybenzoyl chloride 
• 2345-34-8 4-acetyloxy-benzoic acid 
• 99-96-7 4-hydroxy-benzoic acid 
• 110-86-1 pyridine 
• 89932-90-1 bis(4-hydroxyphenyl)methanone oxime 
• 70799-65-4 4-(trimethylsilyloxy)benzoyl chloride 
• 2078-13-9 4-[(trimethylsilyl)oxy]benzoic acid trimethylsilyl ester 
• 345317-68-2 4-Trimethylsilanyloxy-N-(4-trimethylsilanyloxy-phenyl)-benzamide 

Relevant articles and documents

Isouronium and N-hydroxyguanidinium derivatives as Cell growth inhibitors: A comparative study

Based on the results obtained from a computational study on the suitability of the isouronium and N-hydroxyguanidinium cations as hydrogen bond donors/acceptors, the DNA binding of a series of isouronium derivatives was assessed by DNA thermal denaturation experiments and compared to related N-hydroxyguanidines. Due to the poor DNA binding observed, the nature of the diaromatic linker was explored by preparing the corresponding amide-linked bis-isouronium derivative and measuring its DNA affinity. Next, the inhibitory effects of the isouronium derivatives on cell viability were evaluated in two different cancer cell lines providing IC50 values in the range of 36.9-57.4 μM (HL-60, leukemia), and 17.3-33.9 μM (Kelly, neuroblastoma). These values are comparable to those previously found for the N-hydroxyguanidine series. Compounds with the -S- linker (3, 6, and 10) proved to be considerably active in the HL-60 cells and even more active in the Kelly cell line. No correlation was found between DNA minor groove binding and cell growth inhibition; hence, activity may depend on different modes of action. Further studies into the apoptotic potential of these compounds indicated that, besides inhibiting cell viability and proliferation, derivatives 9 and 10, are significant apoptosis-inducers in both cell lines. Results obtained with HL-60 cells suggest that G2/M arrest and subsequent apoptosis induced by compound 10 are associated with microtubular depolymerisation, loss of mitochondrial membrane potential and activation of the caspase cascade. Moreover, the effects of compound 10 on cell viability and apoptosis in two non-cancereous cell lines (NIH3T3 and MCF-10A) indicate none or minimal toxicity.

SuFEx-based synthesis of polysulfates

High-molecular-weight polysulfates are readily formed from aromatic bis(silyl ethers) and bis(fluorosulfates) in the presence of a base catalyst. The reaction is fast and proceeds well under neat conditions or in solvents, such as dimethyl formamide or N-methylpyrrolidone, to provide the desired polymers in nearly quantitative yield. These polymers are more resistant to chemical degradation than their polycarbonate analogues and exhibit excellent mechanical, optical, and oxygen-barrier properties. High-molecular-weight polysulfates are readily formed from aromatic bis(silyl ethers) and bis(fluorosulfates) in the presence of a base catalyst. The polymers were obtained in nearly quantitative yield under neat conditions, they are more resistant to chemical degradation than their polycarbonate analogues and exhibit excellent mechanical, optical, and oxygen-barrier properties. BPA=bisphenol A.

STILBENES AND CHALCONES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.